AAPG
Ascentage Pharma Group International Co., Ltd.
NASDAQ · Healthcare · Biotechnology · CN
$14.96
+10.94%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$14.44
From 52W high−56.40%
Volume18448.00
Market cap$1.40B
P/E (TTM)—
P/S (TTM)14.7x
Div yield—
Key dataNov 4, 2026
Open
$14.44
From 52W high
−56.40%
Volume
18448.00
Market cap
$1.40B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.3x
P/E (TTM)
—
RSI (14)
50.6
MomentumView details →
1D Return
+10.94%
YTD Return
−42.07%
SummaryUpdated Jun 1, 2026
Ascentage Pharma Group International (HKEX:6855) is a clinical-stage biotechnology company founded in 2009 and headquartered in Suzhou, China. The company focuses on developing innovative therapies for cancer treatment, chronic hepatitis B virus infections, and age-related diseases, primarily serving the Chinese mainland market. As a relatively young biotech firm that went public in January 2025, Ascentage operates in the highly specialized field of oncology drug development, with a particular emphasis on targeting specific protein interactions that can restore normal cell death processes in cancer cells.
Similar companies
Latest newsMore news →
Hong Kong-listed innovative-drug stocks rose, with Rongchang Biologics up 13%, WuXi Biologics (Cayman), Inc. and WuXi XDC Cayman, Inc. up more than 12%, and several other named stocks gaining between 5% and more than 11%.11h agoChina’s Center for Drug Evaluation included ASCENTAGE PHARMA GROUP INTERNATIONAL’s lisaftoclax (APG-2575) in its breakthrough therapy designation list for use with acalabrutinib to treat adults with previously untreated CLL/SLL.15d agoChina's National Shanghai Center For New Drug Safety Evaluation & granted Ascentage Pharma's lisaftoclax Breakthrough Therapy Designation in combination with acalabrutinib for treatment-naïve adults with CLL/SLL.15d ago